Company Overview

Tecan Group AG is a Switzerland-based provider of laboratory instruments, automation solutions, and consumables serving the life sciences and diagnostics industries. The company designs, manufactures, and supplies systems that enable automated sample handling, liquid handling, and laboratory workflows used in pharmaceutical research, biotechnology, clinical diagnostics, and applied markets. Its core offerings support drug discovery, genomics, proteomics, and in vitro diagnostics, with customers ranging from large pharmaceutical companies and diagnostic OEMs to academic and government research institutions.

Founded in 1980, Tecan has evolved from a laboratory equipment supplier into a global automation and partnering specialist. Its competitive positioning is based on deep expertise in liquid handling technologies, strong integration of hardware, software, and consumables, and long-term relationships with diagnostic and life science companies that outsource instrument development and manufacturing. The company operates with a strong focus on precision engineering, regulatory compliance, and scalable manufacturing.

Business Operations

Tecan operates through two primary business segments: Life Sciences Business and Partnering Business. The Life Sciences Business generates revenue through the sale of laboratory automation platforms, standalone instruments, reagents, and consumables under the Tecan brand, primarily to pharmaceutical, biotechnology, and academic research customers. This segment also includes software and service contracts that support installed systems across their lifecycle.

The Partnering Business focuses on providing contract design, development, and manufacturing services to diagnostic and life science companies, including OEM instrument platforms and subsystems. This segment leverages proprietary technologies such as precision liquid handling components and automation modules. Key operating subsidiaries supporting this model include Paramit Corporation (contract design and manufacturing) and Cavro Scientific Instruments (precision liquid handling components).

Strategic Position & Investments

Tecan’s strategy emphasizes organic growth through innovation in automation, digital laboratory workflows, and consumables, complemented by selective acquisitions that expand technological capabilities and manufacturing scale. The company has invested significantly in expanding its Partnering Business to capture long-term, recurring revenue from OEM customers outsourcing complex instrument development and production.

Notable acquisitions supporting this strategy include Paramit Corporation, which strengthened Tecan’s U.S.-based manufacturing and design capabilities, and Sias AG, which expanded its laboratory automation portfolio. Tecan is also actively involved in emerging applications such as personalized medicine, molecular diagnostics, and high-throughput screening, aligning its technology roadmap with long-term growth trends in life sciences and diagnostics.

Geographic Footprint

Tecan is headquartered in Europe (Switzerland) and operates a global network of development, manufacturing, and sales sites. The company has significant operational presence in North America, Europe, and Asia-Pacific, with production facilities and R&D centers distributed across Switzerland, Germany, the United States, and other strategic locations.

Its global sales and service organization supports customers in more than 50 countries, reflecting broad international market penetration. The Partnering Business, in particular, has a strong footprint in North America and Europe, enabling close collaboration with multinational diagnostic and life science companies.

Leadership & Governance

Tecan is led by an executive team with long-standing experience in life sciences, automation, and precision manufacturing. The company emphasizes a leadership philosophy centered on technological excellence, customer collaboration, and disciplined capital allocation to support sustainable growth.

Key executives include:

• Achim von Leoprechting – Chief Executive Officer
• Heinz Kundert – Chief Financial Officer

Data inconclusive based on available public sources regarding additional current executive appointments beyond the CEO and CFO.